Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma)

Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma)

The new era of cancer treatments has made immune checkpoint inhibitors (ICIs) and emerging multikinase inhibitors (TKIs) the standards of care, thus drastically improving patient prognoses. Pembrolizumab is an anti-programmed cell death-1 antibody drug, and lenvatinib is a TKI with preferential anti...

Full description

Bibliographic Details
Main Authors: Walid Shalata, Muhammed Iraqi, Baisali Bhattacharya, Vered Fuchs, Laila C. Roisman, Ahron Yehonatan Cohen, Ismaell Massalha, Alexander Yakobson, Manu Prasad, Moshe Elkabets, Angel Porgador, Nir Peled
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cancers
Subjects:
lung adenocarcinoma
NSCLC
malignant pleural mesothelioma
multikinase inhibitor
immune checkpoint inhibitor
lenvatinib
Online Access:https://www.mdpi.com/2072-6694/13/14/3630

Internet

https://www.mdpi.com/2072-6694/13/14/3630

Similar Items